Several previous studies have evaluated the combination of pyrotinib and trastuzumab in the neoadjuvant setting for HER2-postive breast cancer.32,33 In the NeoATP study by Yin and colleagues, the combination of neoadjuvant pyrotinib and trastuzumab with weekly paclitaxel-cisplatin resulted in a remarkable pCR rate of 69.8%.32 Similarly, Xuhong’s study reported a pCR rate of 73.7%.33 However, both studies employed a single-arm design with a relatively small sample size. Here, ERBB2 is linked to breast carcinoma.